Aster Insights and Owkin collaborate to accelerate research in breast cancer
Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, and Owkin, the first end-to-end TechBio unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, are excited to announce a collaboration to accelerate key transatlantic research in breast cancer diagnostics.
Aster Insights will provide advanced multimodal data for a customized cohort of breast cancer patients utilizing the company’s novel and proprietary Avatar dataset. Aster Avatar is the best-in-class research grade scientific intelligence supporting oncology discovery and diagnostic development, and includes comprehensive clinical data combined with multimodal omics, providing the data foundation for progressive AI applications.
Aster Insights and Owkin are in the process of entering into a multi-year relationship with breast cancer designated as the first area of research focus.
Dinesh Divakaran, Vice President of Partnerships, North America at Owkin:
The rate of breast cancer diagnosis across the globe is continually rising and too often, patients will relapse after their initial treatment each year. We are excited to be working with Aster Insights to advance breast cancer research and apply AI to multimodal patient data, ultimately helping us find the right treatment for patients faster.
Dr. Todd Johnson, Chief Growth Officer at Aster Insights:
By combining advanced AI technologies across clinical, genomic, and digital pathology data, we are expediting critical discoveries in cancer testing and treatment. We are thrilled to partner with Owkin on research endeavors that have the potential to transform cancer care for millions of patients worldwide.
About Aster Insights
Aster Insights is the leading provider of scientific and clinical intelligence for oncology discovery. We partner with drug, biologics, diagnostics, and medical device developers to accelerate oncology product discovery and development. Aster Insights leads the Oncology Research Information Exchange Network® (ORIEN), a consortium of the nation's leading cancer centers that conduct Total Cancer Care®, the world's largest and longest running observational research study in oncology. Together, we are changing the way cancer is studied, treated, and prevented. Learn more at www.asterInsights.com and follow us on LinkedIn and Twitter.
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment.
We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
